drugset / Trial / NCT04261907
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
Terminated
6 enrolled
First Affiliated Hospital of Zhejiang University
Ascletis Pharmaceuticals Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia.
Timeline
- Start
- 2020-02-11
- Primary completion
- 2020-04-13
- Completion
- 2020-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lopinavir | Other / unclassified | 200 mg | — |
| Subject | Ritonavir | Other / unclassified | 50 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | TMC310911 | Small molecule | 300 mg | — |